Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is a clinical biopharmaceutical company focused on developing novel product candidates to treat brain health disorders. Its lead product candidate, DT120, is in phase 3 clinical trials for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders. Another key candidate, DT402, is a R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA) currently in phase 2a clinical trials for the treatment of autism spectrum disorder. The company operates in the biotechnology industry within the healthcare sector and is headquartered in New York, New York.

Definium Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol DFTX. The company's stock is traded in U.S. dollars (USD). As a U.S.-based company, its financial reporting and share pricing are denominated in USD, making it accessible to investors on major U.S. stock exchanges.

Definium Therapeutics operates in the healthcare sector, specifically within the biotechnology industry. As a clinical biopharmaceutical company, it focuses on developing therapies for brain health disorders, which falls under the broader biotechnology umbrella. The company's research and development efforts are centered on novel product candidates targeting psychiatric and neurological conditions, positioning it within the biotech subsector of healthcare.

Definium Therapeutics, Inc. is headquartered in New York, New York, United States. The company was formerly known as Mind Medicine (MindMed) Inc. and rebranded to Definium Therapeutics, Inc. in January 2026. This rebranding reflects a strategic shift in focus, though the company continues to develop treatments for brain health disorders. Its primary markets are in the United States, where it conducts clinical trials and seeks regulatory approvals.

Definium Therapeutics has two main product candidates in its pipeline. DT120 is the lead candidate, currently in phase 3 clinical trials for generalized anxiety disorder, major depressive disorder, and other brain health disorders. DT402 is a R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA) and is in phase 2a clinical trials for the treatment of autism spectrum disorder. Both candidates target significant unmet needs in brain health, with DT120 addressing common mood disorders and DT402 focusing on a specific neurodevelopmental condition.